
## Luis M Montuenga

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6577377/publications.pdf Version: 2024-02-01



LUIS M MONTHENCA

#	Article	IF	CITATIONS
1	Complement C5a induces the formation of neutrophil extracellular traps by myeloid-derived suppressor cells to promote metastasis. Cancer Letters, 2022, 529, 70-84.	7.2	51
2	Two cell line models to study multiorganic metastasis and immunotherapy in lung squamous cell carcinoma. DMM Disease Models and Mechanisms, 2022, 15, .	2.4	5
3	Implications of Hyperoxia over the Tumor Microenvironment: An Overview Highlighting the Importance of the Immune System. Cancers, 2022, 14, 2740.	3.7	6
4	YES1: A Novel Therapeutic Target and Biomarker in Cancer. Molecular Cancer Therapeutics, 2022, 21, 1371-1380.	4.1	19
5	Multiplex RNAâ€based detection of clinically relevant <i>MET</i> alterations in advanced nonâ€small cell lung cancer. Molecular Oncology, 2021, 15, 350-363.	4.6	17
6	Molecular profiling of longâ€ŧerm responders to immune checkpoint inhibitors in advanced nonâ€small cell lung cancer. Molecular Oncology, 2021, 15, 887-900.	4.6	24
7	Molecular biomarkers in early stage lung cancer. Translational Lung Cancer Research, 2021, 10, 1165-1185.	2.8	23
8	Bringing Onco-Innovation to Europe's Healthcare Systems: The Potential of Biomarker Testing, Real World Evidence, Tumour Agnostic Therapies to Empower Personalised Medicine. Cancers, 2021, 13, 583.	3.7	13
9	SRC family kinase (SFK) inhibitor dasatinib improves the antitumor activity of anti-PD-1 in NSCLC models by inhibiting Treg cell conversion and proliferation. , 2021, 9, e001496.		42
10	Whole exome sequencing characterization of individuals presenting extreme phenotypes of high and low risk of developing tobacco-induced lung adenocarcinoma. Translational Lung Cancer Research, 2021, 10, 1327-1337.	2.8	3
11	Exosomes in Liquid Biopsy: The Nanometric World in the Pursuit of Precision Oncology. Cancers, 2021, 13, 2147.	3.7	35
12	Immune Cell Infiltrates and Neutrophil-to-Lymphocyte Ratio in Relation to Response to Chemotherapy and Prognosis in Laryngeal and Hypopharyngeal Squamous Cell Carcinomas. Cancers, 2021, 13, 2079.	3.7	5
13	The International Association for the Study of Lung Cancer Molecular Database Project: Objectives, Challenges, and Opportunities. Journal of Thoracic Oncology, 2021, 16, 897-901.	1.1	8
14	Cancer Epigenetic Biomarkers in Liquid Biopsy for High Incidence Malignancies. Cancers, 2021, 13, 3016.	3.7	38
15	A model based on the quantification of complement C4c, CYFRA 21-1 and CRP exhibits high specificity for the early diagnosis of lung cancer. Translational Research, 2021, 233, 77-91.	5.0	15
16	Epigenetic <i>SMAD3</i> Repression in Tumor-Associated Fibroblasts Impairs Fibrosis and Response to the Antifibrotic Drug Nintedanib in Lung Squamous Cell Carcinoma. Cancer Research, 2020, 80, 276-290.	0.9	25
17	Short-term starvation reduces IGF-1 levels to sensitize lung tumors to PD-1 immune checkpoint blockade. Nature Cancer, 2020, 1, 75-85.	13.2	68
18	The IASLC Lung Cancer Staging Project: Analysis of Resection Margin Status and Proposals for Residual Tumor Descriptors for Non–Small Cell Lung Cancer. Journal of Thoracic Oncology, 2020, 15, 344-359.	1.1	87

#	Article	IF	CITATIONS
19	DrugSniper, a Tool to Exploit Loss-Of-Function Screens, Identifies CREBBP as a Predictive Biomarker of VOLASERTIB in Small Cell Lung Carcinoma (SCLC). Cancers, 2020, 12, 1824.	3.7	6
20	Comprehensive Analysis of SWI/SNF Inactivation in Lung Adenocarcinoma Cell Models. Cancers, 2020, 12, 3712.	3.7	6
21	Bringing Greater Accuracy to Europe's Healthcare Systems: The Unexploited Potential of Biomarker Testing in Oncology. Biomedicine Hub, 2020, 5, 1-42.	1.2	15
22	FGFR1 and FGFR4 oncogenicity depends on n-cadherin and their co-expression may predict FGFR-targeted therapy efficacy. EBioMedicine, 2020, 53, 102683.	6.1	15
23	PD-L1 expression correlates with tumor-infiltrating lymphocytes and better prognosis in patients with HPV-negative head and neck squamous cell carcinomas. Cancer Immunology, Immunotherapy, 2020, 69, 2089-2100.	4.2	35
24	Analysis of copy number alterations reveals the lncRNA ALAL-1 as a regulator of lung cancer immune evasion. Journal of Cell Biology, 2020, 219, .	5.2	36
25	Identification of a novel synthetic lethal vulnerability in non-small cell lung cancer by co-targeting TMPRSS4 and DDR1. Scientific Reports, 2019, 9, 15400.	3.3	13
26	The SRC Inhibitor Dasatinib Induces Stem Cell-Like Properties in Head and Neck Cancer Cells that are Effectively Counteracted by the Mithralog EC-8042. Journal of Clinical Medicine, 2019, 8, 1157.	2.4	12
27	YES1 Drives Lung Cancer Growth and Progression and Predicts Sensitivity to Dasatinib. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 888-899.	5.6	50
28	Targeting of TMPRSS4 sensitizes lung cancer cells to chemotherapy by impairing the proliferation machinery. Cancer Letters, 2019, 453, 21-33.	7.2	22
29	The Differential Impact of SRC Expression on the Prognosis of Patients with Head and Neck Squamous Cell Carcinoma. Cancers, 2019, 11, 1644.	3.7	9
30	P2.03-38 Identification of a Novel Synthetic Lethal Vulnerability in Non-Small Cell Lung Cancer by Co-Targeting TMPRSS4 and DDR1. Journal of Thoracic Oncology, 2019, 14, S698-S699.	1.1	1
31	P1.03-26 Genetic and Molecular Profiling of Non-Smoking Related Lung Adenocarcinomas. Journal of Thoracic Oncology, 2019, 14, S428.	1.1	0
32	P1.09-13 Prognostic Value of TMPRSS4 Expression and Its Role as Diagnostic Biomarker by Liquid Biopsy in Early Stage NSCLC. Journal of Thoracic Oncology, 2019, 14, S501.	1.1	0
33	TMPRSS4: A Novel Tumor Prognostic Indicator for the Stratification of Stage IA Tumors and a Liquid Biopsy Biomarker for NSCLC Patients. Journal of Clinical Medicine, 2019, 8, 2134.	2.4	17
34	5 protein-based signature for resectable lung squamous cell carcinoma improves the prognostic performance of the TNM staging. Thorax, 2019, 74, 371-379.	5.6	9
35	Biomarkers in Lung Cancer Screening: Achievements, Promises, and Challenges. Journal of Thoracic Oncology, 2019, 14, 343-357.	1.1	306
36	CT screening for lung cancer: comparison of three baseline screening protocols. European Radiology, 2019, 29, 5217-5226.	4.5	11

#	Article	IF	CITATIONS
37	Whole exome sequencing of germline DNA of individuals presenting extreme phenotypes of high and low risk to develop tobacco-induced lung adenocarcinoma (LUAD) according to KRAS status Journal of Clinical Oncology, 2019, 37, 1540-1540.	1.6	1
38	The IASLC Lung Cancer Staging Project: A Renewed Call to Participation. Journal of Thoracic Oncology, 2018, 13, 801-809.	1.1	49
39	Ruthenium counterstaining for imaging mass cytometry. Journal of Pathology, 2018, 244, 479-484.	4.5	33
40	Blockade of the Complement C5a/C5aR1 Axis Impairs Lung Cancer Bone Metastasis by CXCL16-mediated Effects. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 1164-1176.	5.6	77
41	P1.03-24 TMPRSS4: A Novel Prognostic Biomarker and Therapeutic Target in NSCLC. Journal of Thoracic Oncology, 2018, 13, S521.	1.1	2
42	MA11.06 Prognostic Value of Complement System in NSCLC and its Association with PD-1 and PD-L1 Expression. Journal of Thoracic Oncology, 2018, 13, S394.	1.1	0
43	Complement C4d-specific antibodies for the diagnosis of lung cancer. Oncotarget, 2018, 9, 6346-6355.	1.8	39
44	Comparison of RNA-seq and microarray platforms for splice event detection using a cross-platform algorithm. BMC Genomics, 2018, 19, 703.	2.8	20
45	The oncogenic RNA-binding protein SRSF1 regulates LIG1 in non-small cell lung cancer. Laboratory Investigation, 2018, 98, 1562-1574.	3.7	30
46	The sVEGFR1-i13 splice variant regulates a β1 integrin/VEGFR autocrine loop involved in the progression and the response to anti-angiogenic therapies of squamous cell lung carcinoma. British Journal of Cancer, 2018, 118, 1596-1608.	6.4	18
47	Genomic characterization of individuals presenting extreme phenotypes of high and low risk to develop tobacco-induced lung cancer. Cancer Medicine, 2018, 7, 3474-3483.	2.8	11
48	Epistatic Oncogenic Interactions Determine Cancer Susceptibility to Immunotherapy. Cancer Discovery, 2018, 8, 794-796.	9.4	6
49	A novel proteinâ€based prognostic signature improves risk stratification to guide clinical management in earlyâ€stage lung adenocarcinoma patients. Journal of Pathology, 2018, 245, 421-432.	4.5	29
50	Epigenetic prediction of response to anti-PD-1 treatment in non-small-cell lung cancer: a multicentre, retrospective analysis. Lancet Respiratory Medicine,the, 2018, 6, 771-781.	10.7	167
51	Abstract LB-084: Dasatinib reduces tumor growth in xenograft models derived from human lung tumors with YES1 overexpression. , 2018, , .		1
52	Abstract 2589: Novel predictor of FGFR1 inhibition efficacy in non-small cell lung cancer. , 2018, , .		0
53	Abstract A09: Impaired HLA Class I antigen processing and presentation as a mechanism of acquired Rrsistance to immune checkpoint inhibitors in lung cancer. , 2018, , .		0
54	Strategies to design clinical studies to identify predictive biomarkers in cancer research. Cancer Treatment Reviews, 2017, 53, 79-97.	7.7	80

#	Article	IF	CITATIONS
55	MA17.10 YES1 Kinase is a New Therapeutic Target in Non-small Cell Lung Cancer. Journal of Thoracic Oncology, 2017, 12, S446-S447.	1.1	1
56	A Combined PD-1/C5a Blockade Synergistically Protects against Lung Cancer Growth and Metastasis. Cancer Discovery, 2017, 7, 694-703.	9.4	160
57	Genomic Profiling of Patient-Derived Xenografts for Lung Cancer Identifies <i>B2M</i> Inactivation Impairing Immunorecognition. Clinical Cancer Research, 2017, 23, 3203-3213.	7.0	66
58	Genomic Profiling of Patient-Derived Xenografts for Lung Cancer Identifies <i>B2M</i> Inactivation Impairing Immunorecognition. Clinical Cancer Research, 2017, 23, 3203-3213.	7.0	66
59	Telomere length, COPD and emphysema as risk factors for lung cancer. European Respiratory Journal, 2017, 49, 1601521.	6.7	19
60	Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer. Cancer Discovery, 2017, 7, 1420-1435.	9.4	507
61	P3.07-007 Blockade of the Complement C5a/C5aR1 Axis Impairs Lung Cancer Bone Metastasis. Journal of Thoracic Oncology, 2017, 12, S2300.	1.1	1
62	Coordinated downregulation of Spinophilin and the catalytic subunits of PP1, PPP1CA/B/C, contributes to a worse prognosis in lung cancer. Oncotarget, 2017, 8, 105196-105210.	1.8	14
63	Abstract LB-117: Dasatinib for the treatment of patients with non-small cell lung cancer harboring YES1 amplification. , 2017, , .		1
64	Development of biological tools to assess the role of TMPRSS4 and identification of novel tumor types with high expression of this prometastatic protein. Histology and Histopathology, 2017, 32, 929-940.	0.7	3
65	EventPointer: an effective identification of alternative splicing events using junction arrays. BMC Genomics, 2016, 17, 467.	2.8	31
66	Phenotypic and metabolic features of mouse diaphragm and gastrocnemius muscles in chronic lung carcinogenesis: influence of underlying emphysema. Journal of Translational Medicine, 2016, 14, 244.	4.4	29
67	TMPRSS4 protein overexpression and its promoter hypomethylation predict poor prognosis in squamous lung cancer patients. European Journal of Cancer, 2016, 61, S14.	2.8	Ο
68	sVEGFR1, the VEGFR1 splice variant: A dual function in the response of squamous cell lung carcinoma to anti-angiogenic therapies. European Journal of Cancer, 2016, 61, S125.	2.8	0
69	A largeâ€scale analysis of alternative splicing reveals a key role of QKI in lung cancer. Molecular Oncology, 2016, 10, 1437-1449.	4.6	60
70	TMPRSS4 expression enhances cancer stem cell-like properties in lung cancer cells and correlates with a CSC phenotype in NSCLC patients. European Journal of Cancer, 2016, 61, S51.	2.8	0
71	TMPRSS4 induces cancer stem cell-like properties in lung cancer cells and correlates with ALDH expression in NSCLC patients. Cancer Letters, 2016, 370, 165-176.	7.2	42
72	A Novel Epigenetic Signature for Early Diagnosis in Lung Cancer. Clinical Cancer Research, 2016, 22, 3361-3371.	7.0	113

#	Article	IF	CITATIONS
73	Successful Immunotherapy against a Transplantable Mouse Squamous Lung Carcinoma with Anti–PD-1 and Anti-CD137 Monoclonal Antibodies. Journal of Thoracic Oncology, 2016, 11, 524-536.	1.1	48
74	Targeted depletion of <i>PIK3R2</i> induces regression of lung squamous cell carcinoma. Oncotarget, 2016, 7, 85063-85078.	1.8	16
75	Epigenetic alterations leading to TMPRSS4 promoter hypomethylation and protein overexpression predict poor prognosis in squamous lung cancer patients. Oncotarget, 2016, 7, 22752-22769.	1.8	29
76	Abstract LB-155: Identification of a DNA methylation signature in liquid biopsy for early non-small cell lung cancer (NSCLC) diagnosis. , 2016, , .		0
77	Combined clinical and genomic signatures for the prognosis of early stage non-small cell lung cancer based on gene copy number alterations. BMC Genomics, 2015, 16, 752.	2.8	12
78	Complement activation product C4d in oral and oropharyngeal squamous cell carcinoma. Oral Diseases, 2015, 21, 899-904.	3.0	27
79	Expression of Sirtuin 1 and 2 Is Associated with Poor Prognosis in Non-Small Cell Lung Cancer Patients. PLoS ONE, 2015, 10, e0124670.	2.5	79
80	Análisis de marcadores biológicos en el Proyecto Estratégico de Cáncer de Pulmón CIBERES-RTIC Cáncer-SEPAR. Archivos De Bronconeumologia, 2015, 51, 462-467.	0.8	9
81	Improving Selection Criteria for Lung Cancer Screening. The Potential Role of Emphysema. American Journal of Respiratory and Critical Care Medicine, 2015, 191, 924-931.	5.6	90
82	Cribado de cáncer de pulmón: catorce años de experiencia del Programa Internacional de Detección Precoz de Cáncer de Pulmón con TBDR de Pamplona (P-IELCAP). Archivos De Bronconeumologia, 2015, 51, 169-176.	0.8	59
83	Lung Cancer Screening: Fourteen Year Experience of the Pamplona Early Detection Program (P-IELCAP). Archivos De Bronconeumologia, 2015, 51, 169-176.	0.8	28
84	Stratification of resectable lung adenocarcinoma by molecular and pathological risk estimators. European Journal of Cancer, 2015, 51, 1897-1903.	2.8	10
85	Prognostic signature of early lung adenocarcinoma based on the expression of ribonucleic acid metabolism–related genes. Journal of Thoracic and Cardiovascular Surgery, 2015, 150, 986-992.e11.	0.8	6
86	Biological Marker Analysis as Part of the CIBERES-RTIC Cancer-SEPAR Strategic Project on Lung Cancer. Archivos De Bronconeumologia, 2015, 51, 462-467.	0.8	12
87	Elevated Levels of the Complement Activation Product C4d in Bronchial Fluids for the Diagnosis of Lung Cancer. PLoS ONE, 2015, 10, e0119878.	2.5	23
88	Sphere-derived tumor cells exhibit impaired metastasis by a host-mediated quiescent phenotype. Oncotarget, 2015, 6, 27288-27303.	1.8	9
89	Abstract 2124: Analysis of the functional relevance of novel alternative splicing events in non-small cell lung cancer. , 2015, , .		0
90	Abstract A35: MAX inactivation in small cell lung cancer disrupts the MYC-SWI/SNF programs and is synthetic lethal with BRG1. , 2015, , .		0

#	Article	IF	CITATIONS
91	TGFBI expression is an independent predictor of survival in adjuvant-treated lung squamous cell carcinoma patients. British Journal of Cancer, 2014, 110, 1545-1551.	6.4	21
92	New syngeneic inflammatoryâ€related lung cancer metastatic model harboring double KRAS/WWOX alterations. International Journal of Cancer, 2014, 135, 2516-27.	5.1	14
93	Contrasting responses of nonâ€small cell lung cancer to antiangiogenic therapies depend on histological subtype. EMBO Molecular Medicine, 2014, 6, 539-550.	6.9	21
94	TMPRSS4 regulates levels of integrin α5 in NSCLC through miR-205 activity to promote metastasis. British Journal of Cancer, 2014, 110, 764-774.	6.4	50
95	TRAP1 Regulates Proliferation, Mitochondrial Function, and Has Prognostic Significance in NSCLC. Molecular Cancer Research, 2014, 12, 660-669.	3.4	59
96	Identification of Alternative Splicing Events Regulated by the Oncogenic Factor SRSF1 in Lung Cancer. Cancer Research, 2014, 74, 1105-1115.	0.9	77
97	<i>MAX</i> Inactivation in Small Cell Lung Cancer Disrupts MYC–SWI/SNF Programs and Is Synthetic Lethal with BRG1. Cancer Discovery, 2014, 4, 292-303.	9.4	153
98	RHOB influences lung adenocarcinoma metastasis and resistance in a hostâ€sensitive manner. Molecular Oncology, 2014, 8, 196-206.	4.6	27
99	Genome Wide Association Study (Gwas) for Identification of Single Nucleotide Polymorphisms (Snps) Associated with Individuals Presenting Extreme Phenotypes of Tobacco Induced Non-Small Cell Lung Cancer (Nsclc) Risk. Annals of Oncology, 2014, 25, iv548.	1.2	0
100	Abstract 2477: Max inactivation in small cell lung cancer disrupts the MYC-SWI/SNF programs and is synthetic lethal with BRG1. , 2014, , .		1
101	Identification through genome-wide association study (GWAS) of single nucleotide polymorphisms (SNPs) associated with extreme phenotypes of tobacco-induced non-small cell lung cancer (NSCLC) risk Journal of Clinical Oncology, 2014, 32, 11046-11046.	1.6	1
102	Silica-induced Chronic Inflammation Promotes Lung Carcinogenesis in the Context of an Immunosuppressive Microenvironment. Neoplasia, 2013, 15, 913-IN18.	5.3	33
103	Individual nodule tracking in micro-CT images of a longitudinal lung cancer mouse model. Medical Image Analysis, 2013, 17, 1095-1105.	11.6	18
104	A Prognostic DNA Methylation Signature for Stage I Non–Small-Cell Lung Cancer. Journal of Clinical Oncology, 2013, 31, 4140-4147.	1.6	250
105	Phosphorylated tubulin adaptor protein CRMPâ€2 as prognostic marker and candidate therapeutic target for NSCLC. International Journal of Cancer, 2013, 132, 1986-1995.	5.1	32
106	Multiscalein situanalysis of the role of dyskerin in lung cancer cells. Integrative Biology (United) Tj ETQq0 0 0 rgBT	Oyerlock	2 10 Tf 50 14
107	Investigation of Complement Activation Product C4d as a Diagnostic and Prognostic Biomarker for Lung Cancer. Journal of the National Cancer Institute, 2013, 105, 1385-1393.	6.3	127

108Smokers with CT Detected Emphysema and No Airway Obstruction Have Decreased Plasma Levels of<br/>EGF, IL-15, IL-8 and IL-1ra. PLoS ONE, 2013, 8, e60260.2.59

#	Article	IF	CITATIONS
109	Quantification of Lung Damage in an Elastase-Induced Mouse Model of Emphysema. International Journal of Biomedical Imaging, 2012, 2012, 1-11.	3.9	47
110	Inhibition of Collagen Receptor Discoidin Domain Receptor-1 (DDR1) Reduces Cell Survival, Homing, and Colonization in Lung Cancer Bone Metastasis. Clinical Cancer Research, 2012, 18, 969-980.	7.0	121
111	Re: Inconsistencies in Findings from the Early Lung Cancer Action Project Studies of Lung Cancer Screening. Journal of the National Cancer Institute, 2012, 104, 254-255.	6.3	3
112	Anaphylatoxin C5a Creates a Favorable Microenvironment for Lung Cancer Progression. Journal of Immunology, 2012, 189, 4674-4683.	0.8	219
113	Expression of Tumor-Derived Vascular Endothelial Growth Factor and Its Receptors Is Associated With Outcome in Early Squamous Cell Carcinoma of the Lung. Journal of Clinical Oncology, 2012, 30, 1129-1136.	1.6	63
114	Re: Inconsistencies in Findings From the Early Lung Cancer Action Project Studies of Lung Cancer Screening. Journal of the National Cancer Institute, 2012, 104, 254-254.	6.3	2
115	Progressive lung cancer determined by expression profiling and transcriptional regulation. International Journal of Oncology, 2012, 41, 242-52.	3.3	6
116	Activation of the classical complement pathway in lung cancer: A novel biomarker for diagnosis and prognosis. Immunobiology, 2012, 217, 1135.	1.9	0
117	Smoking history and lung carcinoma: KRAS mutation is an early hit in lung adenocarcinoma development. Lung Cancer, 2012, 75, 156-160.	2.0	17
118	Identification of Novel Deregulated RNA Metabolism-Related Genes in Non-Small Cell Lung Cancer. PLoS ONE, 2012, 7, e42086.	2.5	48
119	Receptor of Activated Protein C Promotes Metastasis and Correlates with Clinical Outcome in Lung Adenocarcinoma. American Journal of Respiratory and Critical Care Medicine, 2012, 186, 96-105.	5.6	45
120	Robust, Standardized Quantification of Pulmonary Emphysema in Low Dose CT Exams. Academic Radiology, 2011, 18, 1382-1390.	2.5	14
121	Evaluation of micro-CT for emphysema assessment in mice: comparison with non-radiological techniques. European Radiology, 2011, 21, 954-962.	4.5	38
122	Inhibitor of Differentiation-1 as a Novel Prognostic Factor in NSCLC Patients with Adenocarcinoma Histology and Its Potential Contribution to Therapy Resistance. Clinical Cancer Research, 2011, 17, 4155-4166.	7.0	47
123	Overexpression of TMPRSS4 in non-small cell lung cancer is associated with poor prognosis in patients with squamous histology. British Journal of Cancer, 2011, 105, 1608-1614.	6.4	64
124	Abstract 5143: The role of VEGFR2 in lung cancer differs between adenocarcinoma and squamous cell carcinoma cell lines. , 2011, , .		0
125	Abstract 2251: High VEGFA pathway expression predicts good prognosis in stage I squamous cell carcinoma of the lung. , 2011, , .		0
126	Abstract 2219: Inhibitor of differentiation-1 is a novel prognostic factor among NSCLC patients with adenocarcinoma histology and contributes to therapy resistance. , 2011, , .		0

#	Article	IF	CITATIONS
127	Longitudinal study of a mouse model of chronic pulmonary inflammation using breath hold gated micro-CT. European Radiology, 2010, 20, 2600-2608.	4.5	34
128	Development of a novel splice array platform and its application in the identification of alternative splice variants in lung cancer. BMC Genomics, 2010, 11, 352.	2.8	25
129	Novel alternatively spliced ADAM8 isoforms contribute to the aggressive bone metastatic phenotype of lung cancer. Oncogene, 2010, 29, 3758-3769.	5.9	42
130	The Oncoprotein SF2/ASF Promotes Non–Small Cell Lung Cancer Survival by Enhancing Survivin Expression. Clinical Cancer Research, 2010, 16, 4113-4125.	7.0	46
131	Complement Factor H Is Elevated in Bronchoalveolar Lavage Fluid and Sputum from Patients with Lung Cancer. Cancer Epidemiology Biomarkers and Prevention, 2010, 19, 2665-2672.	2.5	27
132	VEGF121b and VEGF165b are weakly angiogenic isoforms of VEGF-A. Molecular Cancer, 2010, 9, 320.	19.2	55
133	Complement activation mediates cetuximab inhibition of non-small cell lung cancer tumor growth in vivo. Molecular Cancer, 2010, 9, 139.	19.2	69
134	Abstract 3103: Survivin expression is enhanced by the oncoprotein SF2/ASF in non-small cell lung cancer. , 2010, , .		0
135	Inhibitor of differentiation-1 (Id1): A novel prognostic and predictive factor in lung adenocarcinoma (AC) Journal of Clinical Oncology, 2010, 28, 10611-10611.	1.6	0
136	Alternative Splicing in Lung Cancer. Journal of Thoracic Oncology, 2009, 4, 674-678.	1.1	52
137	Airway segmentation and analysis for the study of mouse models of lung disease using micro-CT. Physics in Medicine and Biology, 2009, 54, 7009-7024.	3.0	34
138	EUELC project: a multi-centre, multipurpose study to investigate early stage NSCLC, and to establish a biobank for ongoing collaboration. European Respiratory Journal, 2009, 34, 1477-1486.	6.7	15
139	A gene-alteration profile of human lung cancer cell lines. Human Mutation, 2009, 30, 1199-1206.	2.5	113
140	Current challenges in lung cancer early detection biomarkers. European Journal of Cancer, 2009, 45, 377-378.	2.8	11
141	Expression of αCPâ€4 inhibits cell cycle progression and suppresses tumorigenicity of lung cancer cells. International Journal of Cancer, 2008, 122, 1512-1520.	5.1	20
142	Identification of Importin 8 (IPO8) as the most accurate reference gene for the clinicopathological analysis of lung specimens. BMC Molecular Biology, 2008, 9, 103.	3.0	40
143	Frequent BRG1/SMARCA4-inactivating mutations in human lung cancer cell lines. Human Mutation, 2008, 29, 617-622.	2.5	226
144	Analysis of TGFBI overexpression and silencing in the proliferation, migration and chemoresistance of NSCLC cells. European Journal of Cancer, Supplement, 2008, 6, 22.	2.2	0

#	Article	IF	CITATIONS
145	SPACE: an algorithm to predict and quantify alternatively spliced isoforms using microarrays. Genome Biology, 2008, 9, R46.	9.6	26
146	A microRNA DNA methylation signature for human cancer metastasis. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 13556-13561.	7.1	990
147	Telomeres and Telomerase in Lung Cancer. Journal of Thoracic Oncology, 2008, 3, 1085-1088.	1.1	51
148	Molecular characterization of small peripheral lung tumors based on the analysis of fine needle aspirates. Histology and Histopathology, 2008, 23, 33-40.	0.7	16
149	Down-Regulation of Human Complement Factor H Sensitizes Non-Small Cell Lung Cancer Cells to Complement Attack and Reduces In Vivo Tumor Growth. Journal of Immunology, 2007, 178, 5991-5998.	0.8	87
150	Computer Assisted Detection of Cancer Cells in Minimal Samples of Lung Cancer. Annual International Conference of the IEEE Engineering in Medicine and Biology Society, 2007, 2007, 5517-20.	0.5	3
151	Tumour-associated macrophages in nonsmall cell lung cancer: the role of interleukin-10. European Respiratory Journal, 2007, 30, 608-610.	6.7	29
152	Lymphangiogenesis and Lung Cancer. Journal of Thoracic Oncology, 2007, 2, 384-386.	1.1	12
153	Assessing the Relationship Between Lung Cancer Risk and Emphysema Detected on Low-Dose CT of the Chest. Chest, 2007, 132, 1932-1938.	0.8	385
154	Alternative splicing: an emerging topic in molecular and clinical oncology. Lancet Oncology, The, 2007, 8, 349-357.	10.7	230
155	Molecular Analysis of a Multistep Lung Cancer Model Induced by Chronic Inflammation Reveals Epigenetic Regulation of p16, Activation of the DNA Damage Response Pathway. Neoplasia, 2007, 9, 840-IN12.	5.3	86
156	The regenerative nidi of the locust midgut as a model to study epithelial cell differentiation from stem cells. Journal of Experimental Biology, 2006, 209, 2215-2223.	1.7	39
157	Adrenomedullin prevents apoptosis in prostate cancer cells. Regulatory Peptides, 2006, 133, 115-122.	1.9	20
158	Molecular Profiling of Computed Tomography Screen-Detected Lung Nodules Shows Multiple Malignant Features. Cancer Epidemiology Biomarkers and Prevention, 2006, 15, 373-380.	2.5	17
159	Adrenomedullin: An Esoteric Juggernaut of Human Cancers. , 2006, , 453-458.		2
160	Gene expression profiling identifies IL-13 receptor ?2 chain as a therapeutic target in prostate tumor cells overexpressing adrenomedullin. International Journal of Cancer, 2005, 114, 870-878.	5.1	29
161	Adrenomedullin expression in a rat model of acute lung injury induced by hypoxia and LPS. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2005, 288, L536-L545.	2.9	27
162	Early Lung Cancer Detection Using Spiral Computed Tomography and Positron Emission Tomography. American Journal of Respiratory and Critical Care Medicine, 2005, 171, 1378-1383.	5.6	163

#	Article	IF	CITATIONS
163	Targeting hypoxia and angiogenesis through HIF-1alpha inhibition. Cancer Biology and Therapy, 2005, 4, 1055-1062.	3.4	42
164	O-019 Modulation of the classical pathway of complement increasesthe susceptibility of lung cancer cells to complement-mediated lysis. Lung Cancer, 2005, 49, S10.	2.0	0
165	PD-005 Role of the putative tumor suppressor aCP-4 and its alternatively spliced variant aCP-4a in in vitro lung cancer growth. Lung Cancer, 2005, 49, S68.	2.0	0
166	P-967 Combination of MAPK inhibitor CI-1040 and conventional chemotherapeutic agents has synergistic effect in non-small cell lung cancer cell lines. Lung Cancer, 2005, 49, S374.	2.0	0
167	Mitogen-Activated Protein Kinase Phosphatase-1 Is Overexpressed in Non-Small Cell Lung Cancer and Is an Independent Predictor of Outcome in Patients. Clinical Cancer Research, 2004, 10, 3639-3649.	7.0	125
168	Dietary influences over proliferating cell nuclear antigen expression in the locust midgut. Journal of Experimental Biology, 2004, 207, 2255-2265.	1.7	22
169	Expression of Complement Factor H by Lung Cancer Cells. Cancer Research, 2004, 64, 6310-6318.	0.9	108
170	αCP-4, Encoded by a Putative Tumor Suppressor Gene at 3p21, But Not Its Alternative Splice Variant αCP-4a, Is Underexpressed in Lung Cancer. Cancer Research, 2004, 64, 4171-4179.	0.9	27
171	ERK1/2 is activated in non-small-cell lung cancer and associated with advanced tumours. British Journal of Cancer, 2004, 90, 1047-1052.	6.4	166
172	Novel and natural knockout lung cancer cell lines for the LKB1/STK11 tumor suppressor gene. Oncogene, 2004, 23, 4037-4040.	5.9	111
173	Altered expression of adhesion molecules and epithelial–mesenchymal transition in silica-induced rat lung carcinogenesis. Laboratory Investigation, 2004, 84, 999-1012.	3.7	68
174	Relative amounts of antagonistic splicing factors, hnRNP A1 and ASF/SF2, change during neoplastic lung growth: Implications for pre-mRNA processing. Molecular Carcinogenesis, 2004, 41, 187-196.	2.7	63
175	Pigment epithelium-derived factor in the monkey retinal pigment epithelium and interphotoreceptor matrix: apical secretion and distribution. Experimental Eye Research, 2004, 78, 223-234.	2.6	121
176	Adrenomedullin inhibits prostate cancer cell proliferation through a cAMP-independent autocrine mechanism. Biochemical and Biophysical Research Communications, 2004, 322, 878-886.	2.1	16
177	Depressed adrenomedullin in the embryonic transforming growth factor-beta1 null mouse becomes elevated postnatally International Journal of Developmental Biology, 2004, 48, 67-70.	0.6	8
178	Androgen-independent expression of adrenomedullin and peptidylglycine α-amidating monooxygenase in human prostatic carcinoma. Molecular Carcinogenesis, 2003, 38, 14-24.	2.7	16
179	Altered patterns of expression of members of the heterogeneous nuclear ribonucleoprotein (hnRNP) family in lung cancer. Lung Cancer, 2003, 41, 131-143.	2.0	138
180	The diffuse endocrine system: from embryogenesis to carcinogenesis. Progress in Histochemistry and Cytochemistry, 2003, 38, 153-272.	5.1	39

#	Article	IF	CITATIONS
181	Overexpression of adrenomedullin gene markedly inhibits proliferation of PC3 prostate cancer cells in vitro and in vivo. Molecular and Cellular Endocrinology, 2003, 199, 179-187.	3.2	19
182	Effects of Acute Hypoxia and Lipopolysaccharide on Nitric Oxide Synthase-2 Expression in Acute Lung Injury. American Journal of Respiratory and Critical Care Medicine, 2003, 168, 287-296.	5.6	40
183	Detección precoz del cáncer de pulmón por tomografÃa computarizada de baja dosis de radiación: resultados de una muestra de 150 individuos asintomáticos. Medicina ClÃnica, 2003, 121, 41-47.	0.6	3
184	Consensus statements from the Second International Lung Cancer Molecular Biomarkers Workshop: A European strategy for developing lung cancer molecular diagnostics in high risk populations. International Journal of Oncology, 2002, 21, 369-73.	3.3	10
185	Adrenomedullin in mammalian embryogenesis. Microscopy Research and Technique, 2002, 57, 40-54.	2.2	25
186	Adrenomedullin and proadrenomedullin N-terminal 20 peptide in the normal prostate and in prostate carcinoma. Microscopy Research and Technique, 2002, 57, 98-104.	2.2	7
187	Adrenomedullin functions as an important tumor survival factor in human carcinogenesis. Microscopy Research and Technique, 2002, 57, 110-119.	2.2	46
188	CL100 expression is down-regulated in advanced epithelial ovarian cancer and its re-expression decreases its malignant potential. Oncogene, 2002, 21, 4435-4447.	5.9	53
189	Expression of Proadrenomedullin Derived Peptides in the Mammalian Pituitary: Co-Localization of Follicle Stimulating Hormone and Proadrenomedullin N-20 Terminal Peptide-Like Peptide in the Same Secretory Granules of the Gonadotropes. Journal of Neuroendocrinology, 2001, 12, 607-617.	2.6	24
190	Peptidylglycine ?-amidating monooxygenase- and proadrenomedullin-derived peptide-associated neuroendocrine differentiation are induced by androgen deprivation in the neoplastic prostate. International Journal of Cancer, 2001, 94, 28-34.	5.1	18
191	Hyperplasia of Alveolar Neuroendocrine Cells in Rat Lung Carcinogenesis by Silica with Selective Expression of Proadrenomedullin-Derived Peptides and Amidating Enzymes. Laboratory Investigation, 2001, 81, 1627-1638.	3.7	17
192	The relationship between glycogen synthesis, biofilm formation and virulence inSalmonella enteritidis. FEMS Microbiology Letters, 2000, 191, 31-36.	1.8	91
193	A new type of arthropod photoreceptor. Arthropod Structure and Development, 2000, 29, 289-293.	1.4	6
194	Characterization of Pancreatic Endocrine Cells of the European Common Frog Rana temporaria. General and Comparative Endocrinology, 2000, 117, 366-380.	1.8	7
195	Effect of P-glycoprotein modulation with cyclosporin A on cerebrospinal fluid penetration of doxorubicin in non-human primates. Cancer Chemotherapy and Pharmacology, 2000, 45, 207-212.	2.3	36
196	New Molecular Strategies for Early Lung Cancer Detection. Cancer Investigation, 2000, 18, 555-563.	1.3	5
197	Proadrenomedullin NH2-terminal 20 peptide (PAMP) and adrenomedullin bind to teratocarcinoma cellsâ~†. Peptides, 2000, 21, 101-107.	2.4	20
198	Hypoxia-Inducible Factor-1 (HIF-1) Up-Regulates Adrenomedullin Expression in Human Tumor Cell Lines during Oxygen Deprivation: A Possible Promotion Mechanism of Carcinogenesis. Molecular Endocrinology, 2000, 14, 848-862.	3.7	221

#	Article	IF	CITATIONS
199	The relationship between glycogen synthesis, biofilm formation and virulence in Salmonella enteritidis. FEMS Microbiology Letters, 2000, 191, 31-36.	1.8	2
200	Hypoxia-Inducible Factor-1 (HIF-1) Up-Regulates Adrenomedullin Expression in Human Tumor Cell Lines during Oxygen Deprivation: A Possible Promotion Mechanism of Carcinogenesis. Molecular Endocrinology, 2000, 14, 848-862.	3.7	72
201	Adrenomedullin Binding Protein in the Plasma of Multiple Species: Characterization by Radioligand Blotting. Endocrinology, 1999, 140, 4908-4911.	2.8	67
202	Underlying Disease Stress Augments Plasma and Tissue Adrenomedullin (AM) Responses to Endotoxin: Colocalized Increases in AM and Inducible Nitric Oxide Synthase within Pancreatic Islets <sup>1</sup> . Endocrinology, 1999, 140, 5402-5411.	2.8	25
203	Proadrenomedullin N-Terminal 20 Peptide (PAMP) Immunoreactivity in Vertebrate Juxtaglomerular Granular Cells Identified by Both Light and Electron Microscopy. General and Comparative Endocrinology, 1999, 116, 192-203.	1.8	20
204	Expression of Adrenomedullin and Proadrenomedullin N-terminal 20 Peptide in Human and Rat Prostate. Journal of Histochemistry and Cytochemistry, 1999, 47, 1167-1177.	2.5	47
205	Adrenomedullin Binding Protein in the Plasma of Multiple Species: Characterization by Radioligand Blotting. Endocrinology, 1999, 140, 4908-4911.	2.8	25
206	Underlying Disease Stress Augments Plasma and Tissue Adrenomedullin (AM) Responses to Endotoxin: Colocalized Increases in AM and Inducible Nitric Oxide Synthase within Pancreatic Islets. Endocrinology, 1999, 140, 5402-5411.	2.8	5
207	The Role of Adrenomedullin as a Growth Regulatory Peptide in the Normal and Malignant Setting. Journal of Animal Science, 1999, 77, 55.	0.5	15
208	Pigment Epithelium-Derived Factor (PEDF) in the Retina. , 1999, , 519-526.		1
209	In situ detection of AE2 anion-exchanger mRNA in the human liver. Cell and Tissue Research, 1998, 291, 481-488.	2.9	26
210	Metabolic and Immunohistochemical Asessment of Endocrine Pancreatic Function After Orthotopic Multivisceral Transplantation. Transplantation Proceedings, 1998, 30, 633.	0.6	0
211	Circulating adrenomedullin in cirrhosis: relationship to hyperdynamic circulation. Journal of Hepatology, 1998, 29, 250-256.	3.7	54
212	Coordinate Expression of Transforming Growth Factor-β1 and Adrenomedullin in Rodent Embryogenesis. Endocrinology, 1998, 139, 3946-3957.	2.8	32
213	Expression of Heterogeneous Nuclear Ribonucleoprotein A2/B1 Changes with Critical Stages of Mammalian Lung Development. American Journal of Respiratory Cell and Molecular Biology, 1998, 19, 554-562.	2.9	47
214	Coordinate Expression of Transforming Growth Factor-Â1 and Adrenomedullin in Rodent Embryogenesis. Endocrinology, 1998, 139, 3946-3957.	2.8	11
215	Expression of Adrenomedullin and Its Receptor during Embryogenesis Suggests Autocrine or Paracrine Modes of Action. Endocrinology, 1997, 138, 440-451.	2.8	191
216	Adrenomedullin expression in the mouse mammary gland: evidence for the mature form in milk. Journal of Molecular Endocrinology, 1997, 19, 279-289.	2.5	25

#	Article	IF	CITATIONS
217	Expression of Adrenomedullin and Its Receptor during Embryogenesis Suggests Autocrine or Paracrine Modes of Action. Endocrinology, 1997, 138, 440-451.	2.8	60
218	Presence of Locusta diuretic hormone in endocrine cells of the ampullae of locust Malpighian tubules. Cell and Tissue Research, 1996, 285, 331-339.	2.9	26
219	Distribution of peptidyl-glycine alpha-amidating mono-oxygenase (PAM) enzymes in normal human lung and in lung epithelial tumors Journal of Histochemistry and Cytochemistry, 1996, 44, 3-12.	2.5	36
220	Detection of nitric oxide synthase (NOS) in somatostatin-producing cells of human and murine stomach and pancreas Journal of Histochemistry and Cytochemistry, 1996, 44, 339-346.	2.5	44
221	Inducible nitric oxide synthase in human lymphomononuclear cells activated by synthetic peptides derived from extracellular matrix proteins. FEBS Letters, 1995, 357, 121-124.	2.8	26
222	Neuroendocrine Diffuse System of the Respiratory Tract of Rana temporaria: An Immunocytochemical Study. General and Comparative Endocrinology, 1995, 100, 145-161.	1.8	8
223	Immunocytochemical localization of a vacuolar-type ATPase in Malpighian tubules of the ant Formica polyctena. Cell and Tissue Research, 1995, 282, 343-350.	2.9	1
224	Production of Regulatory Factors in the Respiratory System of Vertebrates. Animal Biology, 1994, 45, 33-37.	0.4	0
225	Endothelin-like Immunoreactivity in Midgut Endocrine Cells of the Desert Locust, Locusta migratoria. General and Comparative Endocrinology, 1994, 93, 9-20.	1.8	15
226	Osmoregulatory-like mitochondria-rich cells in the developing pancreatic ducts of young anuran tadpoles. Journal of Morphology, 1993, 216, 339-350.	1.2	2
227	Immunohistochemical colocalization of 7B2 and 5HT in the neuroepithelial bodies of the lung of Rana temporaria. Cell and Tissue Research, 1993, 273, 137-140.	2.9	10
228	Regulatory peptides in gut endocrine cells and nerves in the starfish Marthasterias glacialis. Cell and Tissue Research, 1993, 271, 375-380.	2.9	15
229	Nitric oxide synthase-immunoreactive neurons in human and porcine respiratory tract. Neuroscience Letters, 1993, 162, 121-124.	2.1	35
230	Localization of amidating enzymes (PAM) in rat gastrointestinal tract Journal of Histochemistry and Cytochemistry, 1993, 41, 1617-1622.	2.5	22
231	Immunocytochemical localization of peptidylglycine alpha-amidating monooxygenase enzymes (PAM) in human endocrine pancreas Journal of Histochemistry and Cytochemistry, 1993, 41, 375-380.	2.5	28
232	Simultaneous immunostaining method for localization of bromodeoxyuridine and calcitonin gene-related peptide Journal of Histochemistry and Cytochemistry, 1992, 40, 1121-1128.	2.5	15
233	CGRP-immunoreactive endocrine cell proliferation in normal and hypoxic rat lung studied by immunocytochemical detection of incorporation of 5?-bromodeoxyuridine. Cell and Tissue Research, 1992, 268, 9-15.	2.9	33
234	A novel granular cell type of locust Malpighian tubules: ultrastructural and immunocytochemical study. Cell and Tissue Research, 1992, 268, 123-130.	2.9	8

#	Article	IF	CITATIONS
235	Malpighian tubules ofFormica polyctena (Hymenoptera): Light and electron microscopic study. Journal of Morphology, 1992, 214, 159-171.	1.2	14
236	Development of the endocrine pancreas during larval phases of Rana temporaria. Cell and Tissue Research, 1991, 264, 139-150.	2.9	16